The response of tumour vasculature to angiotensin II revealed by its systemic and local administration to 'tissue-isolated' tumours
- PMID: 7669567
- PMCID: PMC2033914
- DOI: 10.1038/bjc.1995.379
The response of tumour vasculature to angiotensin II revealed by its systemic and local administration to 'tissue-isolated' tumours
Abstract
A tissue-isolated preparation of the P22 rat carcinosarcoma was used to investigate the tumour vascular response to angiotensin II (ATII). In particular, the relative importance of systemic and local tumour factors was assessed by comparing tumour vascular resistance during systemic administration of ATII and during administration directly into the tumour-supplying artery. The effect of hypervolaemia on tumour vascular resistance was determined as well as the effect of ATII on oxygen metabolism. Tumour vascular resistance was increased by ATII in a dose-dependent manner. The response was biphasic with an initial peak in resistance followed by a lower plateau phase. Systemic administration of ATII was more effective in increasing tumour vascular resistance than direct administration. This suggests that systemic administration is not causing any reopening of previously collapsed tumour blood vessels. Further evidence for this is that hypervolaemia caused no reduction in tumour vascular resistance and that there was no difference in oxygen extraction by tumours between groups treated with systemically and directly administered ATII. A heterogeneous distribution of ATII receptors in the P22 tumour is a more likely explanation for the known heterogeneity of blood flow response to ATII.
Similar articles
-
Spatial heterogeneity of tumour blood flow modification induced by angiotensin II: relationship to receptor distribution.Int J Cancer. 1996 Mar 1;65(5):658-63. doi: 10.1002/(SICI)1097-0215(19960301)65:5<658::AID-IJC16>3.0.CO;2-3. Int J Cancer. 1996. PMID: 8598318
-
A comparative study of tumour blood flow modification in two rat tumour systems using endothelin-1 and angiotensin II: influence of tumour size on angiotensin II response.Int J Cancer. 1996 Sep 4;67(5):730-8. doi: 10.1002/(SICI)1097-0215(19960904)67:5<730::AID-IJC23>3.0.CO;2-7. Int J Cancer. 1996. PMID: 8782666
-
Resistance to flow through tissue-isolated transplanted rat tumours located in two different sites.Br J Cancer. 1993 Jun;67(6):1337-41. doi: 10.1038/bjc.1993.247. Br J Cancer. 1993. PMID: 8512817 Free PMC article.
-
Modification of tumour blood flow using the hypertensive agent, angiotensin II.Br J Cancer. 1993 May;67(5):981-8. doi: 10.1038/bjc.1993.180. Br J Cancer. 1993. PMID: 8494732 Free PMC article.
-
Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability.Cancer Res. 2001 Sep 1;61(17):6413-22. Cancer Res. 2001. PMID: 11522635
Cited by
-
Disparate responses of tumour vessels to angiotensin II: tumour volume-dependent effects on perfusion and oxygenation.Br J Cancer. 2000 Jul;83(2):225-31. doi: 10.1054/bjoc.2000.1229. Br J Cancer. 2000. PMID: 10901375 Free PMC article.
-
Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy.Sci Transl Med. 2017 Oct 4;9(410):eaan5616. doi: 10.1126/scitranslmed.aan5616. Sci Transl Med. 2017. PMID: 28978752 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources